PFE · News · 20260814N
Product Demand Trends
PFIZER INC · 2026-08-14 · Importance 17 · Surprise 24 · In source text
A real-world study in South Korea found that Paxlovid was effective in older adults treated in long-term care hospitals. Compared with matched non-users, Paxlovid users had lower rates of severe COVID-19, mortality, and deterioration in daily functioning. The findings support continued use of Paxlovid in high-risk populations and may strengthen the product’s positioning in the COVID-19 treatment market.
Key facts
- Pfizer halted an unfinished $350 million biomanufacturing facility in Everett after acquiring Seagen in 2023. source
- Pfizer Inc. has completed a real-world study in Korea on Paxlovid demonstrating its effectiveness in older adults within long-term care hospitals against severe COVID-19, mortality, and decline in daily function. source
- Pfizer has agreed to a $44 million class action settlement over its oral prescription medication Chantix. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | negative | committed | -0.1% | Pfizer halted an unfinished $350 million biomanufacturing facility in Everett after acquiring Seagen in 2023. |